Kamada KMDA 深 滬
等待開盤 09-23 09:30:00 美东时间
8.87
+0.130
+1.49%
華盛通- 最 高8.91
- 今 開8.71
- 成交量 12.58万股
- 最 低 8.68
- 昨 收 8.74
- 總市值 5.12亿
- 52周最高 8.96
- 市盈率 靜 25.62
- 換手率 0.22%
- 52周最低 6.08
- 委 比 23.41%
- 總股本 5771.03万
- 歷史最高 17.33
- 量 比 0.92
- 振 幅 2.63%
- 歷史最低 2.40
- 每 手 1
- 風險率 0.76%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Kamada to Present at the H.C. Wainwright 28th Annual Global Investment Conference
Kamada Ltd., a global biopharmaceutical company specializing in rare and serious conditions, announced that CEO Amir London will present at the H.C. Wainwright 28th Annual Global Investment Conference on September 15, 2026. The presentation will be live streamed, with a replay available for 30 days. Investors can arrange one-on-one meetings with Mr. London through their H.C. Wainwright representative. Kamada focuses on organic growth, partnership...
09-10 11:00
Kamada Secures Israeli Tax Ruling on Withholding for September Dividend
Kamada ( ($IL:KMDA) ) just unveiled an update. On September 3, 2026, Kamada Ltd...
09-04 07:30
Kamada Updates on Withholding Tax Procedures on Previously Announced Cash Dividend to Shareholders
Kamada Ltd. announced it has obtained a tax ruling from the Israel Tax Authority regarding a cash dividend of $0.17 per share, totaling approximately $9.8 million, to be paid on September 17, 2026. Shareholders trading on Nasdaq who are residents of countries with an Israeli tax treaty may qualify for a reduced withholding tax rate, while Israeli corporate shareholders may be exempt from withholding tax. Documentation must be submitted to the Tax...
09-03 20:01
Kamada declares $0.17 dividend
Kamada (KMDA) declares $0.17/share dividend. Payable Sept. 17; for shareholders of record Aug. 27; ex-div Aug. 27. See KMDA Dividend Scorecard, Yield Chart, & Dividend Growth. More on Kamada Kamada Lt...
08-17 20:29
Kamada CFO Chaime Orlev to step down
Kamada (KMDA) said CFO Chaime Orlev will step down from his role effective December 31, 2026, to pursue other opportunities. The company has begun searching for his successor. Orlev, who has served as...
08-12 19:27
Kamada Affirms FY2026 Sales Guidance of $200.000M-$205.000M vs $202.048M Est
Kamada (NASDAQ:KMDA) affirms FY2026 sales outlook from $200.000 million-$205.000 million to $200.000 million-$205.000 million vs $202.048 million estimate.
08-12 19:07
Kamada Q2 EPS $0.16 Beats $0.12 Estimate, Sales $54.921M Beat $50.657M Estimate
Kamada (NASDAQ:KMDA) reported quarterly earnings of $0.16 per share which beat the analyst consensus estimate of $0.12 by 33.33 percent. This is a 23.08 percent increase over earnings of $0.13 per share from the same period last year. The company reported quarterly sales of $54.921 million which bea...
08-12 19:07
Kamada Announces Planned Transition of Chief Financial Officer
Kamada Ltd. announced that Chief Financial Officer Chaime Orlev will transition out of his role effective December 31, 2026, to pursue other opportunities. Kamada is currently searching for a successor, and Orlev will provide transitional support to the new CFO. CEO Amir London thanked Orlev for his nine years of leadership and contributions to the company's growth. Orlev expressed gratitude for his tenure and confidence in Kamada's continued gro...
08-12 11:00
Kamada to Announce Second Quarter and First Half Ended June 30, 2026 Financial Results on August 12, 2026
Kamada Ltd. will release its second-quarter and first-half 2026 financial results on August 12, 2026, before U.S. markets open. Management will host a conference call at 8:30am ET to discuss the results and answer questions. The call can be accessed via phone or webcast. Kamada, a global biopharmaceutical company, focuses on rare and serious conditions, with a portfolio of six FDA-approved plasma-derived products and a strategy centered on organi...
08-05 11:00
Kamada Highlights Results Of An Investigator-initiated Study Of Cytogam, The Company’s Cytomegalovirus Immune Globulin, In The Management Of Cytomegalovirus In Solid Organ Transplantation
Kamada Ltd. (NASDAQ:KMDA, TASE: KMDA.TA))), a global biopharmaceutical company with a portfolio of marketed products indicated for rare and serious conditions and a leader in the specialty plasma-derived therapies field, today highlighted results of an Investigator-Initiated Study recently presented...
07-13 19:19
